Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | JMJD6 | Q6NYC1 | 5/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 4/20 | 0.42 |
| ▸ | NOS2 | P35228 | 4/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9227312 | 0.81 | EGFR (0.54) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3492541 | 0.73 | MAPT (0.66) | MEN1NPC1TSHRRAB9AKMT2A | |
| SCHEMBL4258986 | 0.73 | NPC1 (0.43) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL6935872 | 0.73 | JMJD6 (0.51) | NPC1RAB9AKMT2ASMN1; SMN2JMJD6 | |
| SCHEMBL3475607 | 0.72 | HRH4 (0.54) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL3477939 | 0.72 | HRH4 (0.53) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL3476758 | 0.72 | HRH4 (0.50) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL3477290 | 0.71 | HRH4 (0.55) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL3477072 | 0.71 | FAAH (0.56) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL15077835 | 0.70 | JMJD6 (0.46) | NPC1RAB9ASMN1; SMN2JMJD6PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004188-B1 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-01 | — | — | EP | disclosed |
| US-7589087-B2 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-2004188-A4 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | disclosed |
| EP-2004188-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007117400-A2 | BENZOIMIDAZOL-2-YL PYRIDINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232616-A1 | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | MEN1 3032/4885NPC1 3241/4885TP53 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.